Sarepta Therapeutics, Inc.
Cash Flow History
| Fiscal Year | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| FY2009 | $-8.8M | $-9.7M | $931.0K | $2.4M |
| FY2010 | $-15.2M | $-16.0M | $832.0K | $3.2M |
| FY2011 | $-23.7M | $-24.9M | $1.2M | $3.1M |
| FY2012 | $-29.7M | $-29.8M | $108.0K | $3.1M |
| FY2013 | $-64.7M | $-67.1M | $2.4M | $11.1M |
| FY2014 | $-128.5M | $-154.0M | $25.4M | $20.3M |
| FY2015 | $-149.5M | $-152.9M | $3.4M | $32.1M |
| FY2016 | $-245.8M | $-251.2M | $5.3M | $30.0M |
| FY2017 | $-232.0M | $-244.0M | $12.0M | $30.5M |
| FY2018 | $-388.7M | $-449.8M | $61.2M | $50.1M |
| FY2019 | $-456.5M | $-516.1M | $59.6M | $78.6M |
| FY2020 | $107.5M | $25.3M | $82.2M | $108.1M |
| FY2021 | $-443.2M | $-481.7M | $38.5M | $113.9M |
| FY2022 | $-325.3M | $-356.2M | $30.8M | $233.0M |
| FY2023 | $-501.0M | $-577.1M | $76.1M | $182.5M |
| FY2024 | $-205.8M | $-342.7M | $137.0M | $184.3M |
| FY2025 | $-205.5M | $-307.5M | $102.0M | $123.4M |